
XENE
Healthcare · Biotechnology · $3.98B market cap
$40.48-0.52 (-1.3%)Nov 13, 4:00 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +4.2% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 1, 2027 · upcoming | After the close | -1.15 | — | — |
| Nov 9, 2026 | After the close | -1.14 | -1.11 | +2.6% |
| Aug 6, 2026 | After the close | -1.16 | -1.11 | +4.3% |
| May 7, 2026 | After the close | -1.20 | -1.17 | +2.5% |
| Feb 26, 2026 | Time not confirmed | -1.20 | -1.31 | -9.2% |
| Nov 3, 2025 | After the close | -1.16 | -1.15 | +0.9% |
| Aug 11, 2025 | After the close | -0.99 | -1.07 | -8.1% |
| May 12, 2025 | After the close | -0.90 | -0.83 | +7.8% |
| Feb 26, 2025 | Before the open | -0.84 | -0.84 | -0.1% |
| Nov 12, 2024 | After the close | -0.79 | -0.81 | -2.5% |
| Aug 8, 2024 | After the close | -0.68 | -0.75 | -10.3% |
| May 9, 2024 | After the close | -0.65 | -0.62 | +4.6% |
| Feb 29, 2024 | After the close | -0.76 | -0.64 |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary…
| +15.8% |
| Nov 8, 2023 | After the close | -0.75 | -0.73 | +2.7% |
| Aug 9, 2023 | After the close | -0.67 | -0.72 | -7.5% |
| May 9, 2023 | After the close | -0.60 | -0.63 | -5.0% |
| Mar 1, 2023 | After the close | -0.58 | -0.57 | +1.7% |
| Nov 8, 2022 | After the close | -0.53 | -0.57 | -7.5% |
| Aug 9, 2022 | After the close | -0.50 | -0.55 | -10.0% |
| May 10, 2022 | After the close | -0.41 | -0.35 | +14.6% |
| Mar 1, 2022 | After the close | -0.37 | -0.48 | -29.7% |
| Nov 10, 2021 | After the close | -0.44 | -0.36 | +18.2% |
| Aug 11, 2021 | After the close | -0.49 | -0.51 | -4.1% |
| May 11, 2021 | After the close | -0.39 | -0.42 | -7.7% |
| Mar 1, 2021 | After the close | -0.40 | -0.34 | +15.0% |
| Nov 5, 2020 | After the close | -0.17 | -0.25 | -47.1% |
| Aug 5, 2020 | After the close | -0.20 | -0.00 | +97.5% |
| May 21, 2020 | After the close | -0.31 | -0.22 | +29.0% |
| Mar 9, 2020 | After the close | -0.48 | -0.42 | +12.5% |
| Nov 5, 2019 | After the close | -0.46 | -0.33 | +28.3% |
| Aug 6, 2019 | After the close | -0.45 | -0.37 | +17.8% |
| May 7, 2019 | After the close | -0.37 | -0.42 | -13.5% |
| Mar 6, 2019 | After the close | -0.37 | -0.29 | +21.6% |
| Nov 6, 2018 | After the close | -0.40 | -0.63 | -57.5% |
| Aug 7, 2018 | After the close | -0.49 | -0.45 | +8.2% |
| May 8, 2018 | After the close | -0.48 | -0.46 | +4.2% |
| Mar 7, 2018 | After the close | -0.11 | -0.45 | -309.1% |